ACTRIMS 2024 | Developments in MS reparative treatments

Christian Cordano, MD, PhD, UCSF Weill Institute for Neurosciences, San Francisco, CA, comments on the latest developments in reparative treatment research in multiple sclerosis (MS). Despite a wealth of medications able to control relapses in MS, progression independent of relapse activity has been shown to drive disability accumulation and no treatments are able to reverse existing damage. Dr Cordano comments on recent studies in this space. He advocates studying synaptic loss and remyelination concurrently, emphasizing their interconnectedness. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.